RISVAN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Risvan, and when can generic versions of Risvan launch?
Risvan is a drug marketed by Labs Farms Rovi Sa and is included in one NDA. There are fourteen patents protecting this drug.
This drug has one hundred and eighty-two patent family members in thirty-six countries.
The generic ingredient in RISVAN is risperidone. There are thirty drug master file entries for this compound. Thirty-nine suppliers are listed for this compound. Additional details are available on the risperidone profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Risvan
A generic version of RISVAN was approved as risperidone by APOTEX INC on September 15th, 2008.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for RISVAN?
- What are the global sales for RISVAN?
- What is Average Wholesale Price for RISVAN?
Summary for RISVAN
International Patents: | 182 |
US Patents: | 14 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Patent Applications: | 2,495 |
What excipients (inactive ingredients) are in RISVAN? | RISVAN excipients list |
DailyMed Link: | RISVAN at DailyMed |
Pharmacology for RISVAN
Drug Class | Atypical Antipsychotic |
US Patents and Regulatory Information for RISVAN
RISVAN is protected by fourteen US patents and one FDA Regulatory Exclusivity.
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Labs Farms Rovi Sa | RISVAN | risperidone | FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 214835-002 | Mar 29, 2024 | DISCN | Yes | No | 11,752,093 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
Labs Farms Rovi Sa | RISVAN | risperidone | FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 214835-002 | Mar 29, 2024 | DISCN | Yes | No | 10,335,366 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
Labs Farms Rovi Sa | RISVAN | risperidone | FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 214835-001 | Mar 29, 2024 | DISCN | Yes | No | 11,752,092 | ⤷ Subscribe | ⤷ Subscribe | ||||
Labs Farms Rovi Sa | RISVAN | risperidone | FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 214835-002 | Mar 29, 2024 | DISCN | Yes | No | 11,173,110 | ⤷ Subscribe | ⤷ Subscribe | ||||
Labs Farms Rovi Sa | RISVAN | risperidone | FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 214835-002 | Mar 29, 2024 | DISCN | Yes | No | 10,881,605 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for RISVAN
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Laboratorios Farmacéuticos Rovi, S.A. | Okedi | risperidone | EMEA/H/C/005406 Treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone. |
Authorised | no | no | no | 2022-02-14 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for RISVAN
See the table below for patents covering RISVAN around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
South Africa | 201501426 | INJECTABLE COMPOSITIONS COMPRISING LETROZOLE OR ANASTROZOLE | ⤷ Subscribe |
South Korea | 20150015020 | Paliperidone implant formulation | ⤷ Subscribe |
Portugal | 2394663 | ⤷ Subscribe | |
Brazil | 112014029209 | formulação para implante de risperidona ou paliperidona | ⤷ Subscribe |
Morocco | 37870 | Compositions injectables comprenant du létrozole ou de l'anastrozole | ⤷ Subscribe |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for RISVAN
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0196132 | 94C0008 | Belgium | ⤷ Subscribe | PRODUCT NAME: RISPERIDONE; NAT REG.: 2 S 414 F 3 19940527; FIRST REG.: GB 0242/0186 19921208 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
RISVAN Market Analysis and Financial Projection Experimental
More… ↓